GC Biopharma Corp. (006280.KS)
| Previous Close | 114,100.00 |
| Open | 115,200.00 |
| Bid | 114,700.00 x 0 |
| Ask | 115,000.00 x 0 |
| Day's Range | 114,100.00 - 115,700.00 |
| 52 Week Range | 93,000.00 - 131,100.00 |
| Volume | |
| Avg. Volume | 20,196 |
| Market Cap | 1.308T |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | 1,500.00 (1.31%) |
| Ex-Dividend Date | Dec 27, 2023 |
| 1y Target Est | 142,667.00 |
PR NewswireGC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphoma, and real-world data for the anticancer immunotherapy drug 'Immuncell-LC' at the AACR Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
PR NewswireGC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.
GC Cell, a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell. This important partnership lays the foundation to bring GC Cells' proven cell-based immunotherapy, Immuncell-LC to the North American market. The execution of a Process Transfer Agreement with BioCentriq effectively lays the foundation for the U.S. launch of Immuncell-LC through utilization o
PR NewswireGC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024
GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.
